Prophylactic Donor Lymphocyte Infusions
Showing 1 - 25 of 6,946
Hematologic Malignancy Trial in Saint Petersburg (Prophylactic Donor lymphocytes infusions, Preventive Donor lymphocytes
Recruiting
- Hematologic Malignancy
- Prophylactic Donor lymphocytes infusions
- Preventive Donor lymphocytes infusions
-
Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
Aug 16, 2021
Hematologic Malignancy, Haplo-identical Stem Cell Transplantation Trial (CD45RAneg cells, prepared from mononuclear cell
Not yet recruiting
- Hematologic Malignancy
- Haplo-identical Stem Cell Transplantation
- CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
- (no location specified)
Oct 1, 2021
Hematologic Tumors Trial run by the NCI (donor lymphocyte infusion, Cyclophosphamide, Busulfan)
Suspended
- Hematologic Neoplasms
- donor lymphocyte infusion
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 30, 2022
Hematologic Malignancy Trial in Tuebingen,, Tuebingen (CD45RA depleted donor lymphocyte infusion (DLI))
Recruiting
- Hematologic Malignancy
- CD45RA depleted donor lymphocyte infusion (DLI)
-
Tuebingen,, Germany
- +1 more
Jul 13, 2023
Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte
Recruiting
- Lymphoid Leukemia, Acute
- +2 more
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc
May 24, 2022
MDS, Leukemia, Myeloid, Acute Trial in London (DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell
Unknown status
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)
- DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
-
London, United KingdomKing's College Hospital NHS Foundation Trust
Apr 1, 2020
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia Trial in Los Angeles (radiation, procedure, biological, drug)
Active, not recruiting
- Multiple Myeloma
- +4 more
- Total Body Irradiation
- +5 more
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Dec 21, 2022
Severe Combined Immunodeficiency Trial in Memphis (drug, device, other)
Recruiting
- Severe Combined Immunodeficiency
- Anti-thymocyte globulin (rabbit)
- +5 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Oct 6, 2021
Multiple Myeloma Trial in New York (busulfan, melphalan and fludarabine)
Completed
- Multiple Myeloma
- busulfan, melphalan and fludarabine
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Nov 4, 2021
Refractory Acute Myeloid Leukemia Trial in Paris (Sequential Packaging (SET), Transfusion graft, Prevention of GVHD)
Completed
- Refractory Acute Myeloid Leukemia
- Sequential Packaging (SET)
- +4 more
-
Paris, FranceService d'hématologie Clinique Hôpital Saint Antoine
Jul 22, 2022
Tumor Metastasis Trial run by the NHLBI (methotrexate, Cyclosporin)
Terminated
- Neoplasm Metastasis
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 8, 2021
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic Trial run by the NHLBI (Miltenyi
Completed
- Leukemia, Myeloid, Acute
- +2 more
- Miltenyi Magnetic cell sorter for CD3
-
Bethesda, MarylandNational Institutes of Health
Oct 7, 2020
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Tumor Trial in Buffalo (donor lymphocytes)
Completed
- Leukemia
- +3 more
- donor lymphocytes
-
Buffalo, New YorkRoswell Park Cancer Institute
Aug 21, 2020
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid
Completed
- Minimal Residual Disease
- +3 more
- Daratumumab
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 2, 2022
Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)
Recruiting
- Myeloid Malignancies
- Lymphoid Malignancies
- NK Cell enriched-DLI only
- NK-DLI + DUK-CPG-001
-
Durham, North CarolinaDuke University Health System
Mar 8, 2022
Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Duesseldorf (Lenalidomide, Azacitidine, Donor
Completed
- Leukemia, Myeloid, Acute
- +2 more
- Lenalidomide
- +2 more
-
Duesseldorf, NRW, GermanyUniversity Hospital Duesseldorf, Dept. of Hematology, Oncology a
May 26, 2020
Acute Myeloid Leukaemia (AML), MDS (MDS) Trial in Germany, Netherlands (Panobinostat)
Active, not recruiting
- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndromes (MDS)
-
Stuttgart, Baden-Württemberg, Germany
- +18 more
Dec 13, 2021
Acute Lymphocytic Leukemia Trial in Philadelphia (CART-19)
Terminated
- Acute Lymphocytic Leukemia
- CART-19
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 7, 2020
Immunodeficiency Trial in Charlotte (Infusion of donor lymphocytes)
Terminated
- Immunodeficiency
- Infusion of donor lymphocytes
-
Charlotte, North CarolinaLevine Children's Hospital, Carolinas Medical Center
Apr 20, 2022
Leukemia Trial in Badalona, Hospitalet de Llobregat, Barcelona (DLI of the 20 fraction of the UCBT)
Completed
- Leukemia
- DLI of the 20 fraction of the UCBT
-
Badalona, Barcelona, Spain
- +4 more
Dec 3, 2021
Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)
Withdrawn
- Leukemia
- Stem Cell Transplantation
-
Munich, Bavaria, Germany3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022
Sickle Cell Disease Trial in Memphis (hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and
Recruiting
- Sickle Cell Disease
- hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus
- hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 5, 2022
Advanced Sarcoma Trial (NKG2D-CAR memory T cell)
Not yet recruiting
- Advanced Sarcoma
- NKG2D-CAR memory T cell
- (no location specified)
Oct 17, 2023
Acute Myeloid Leukemia, in Relapse Trial in Freiburg (Bicanorm)
Completed
- Acute Myeloid Leukemia, in Relapse
-
Freiburg, Baden-Württemberg, GermanyMedical Center University of Freiburg
Mar 24, 2020